(BMY) Bristol-Myers Squibb - Ratings and Ratios

Bristol-Myers Squibb Company (NYSE:BMY) is a global leader in the pharmaceutical industry, specializing in the discovery, development, and distribution of innovative biopharmaceutical products. With a strong focus on immunology and oncology, the company has established itself as a pioneer in these fields. Their extensive product portfolio includes blockbuster drugs such as Eliquis and Opdivo, which have significantly impacted the treatment of atrial fibrillation and various cancers, respectively. Recent product launches and ongoing research and development efforts underscore their commitment to advancing patient care.

The companys distribution network is robust, ensuring their products reach a wide audience, including wholesalers, hospitals, and government agencies. This infrastructure supports their mission to deliver life-saving medications globally. Founded in 1887 and headquartered in Princeton, New Jersey, Bristol-Myers Squibb has a long-standing history of innovation and contribution to healthcare.

Ticker Symbol: BMY Exchange: NYSE Type: common stock Country Origin: United States GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 13,329,080 Last Price: 49.23 SMA 20: 55.47 SMA 50: 56.80 SMA 200: 52.57 ATR: 1.99

Market Cap: 112,298.40M USD P/E: None P/E Forward: 8.18 P/B: 6.89 P/S: 2.33 RoE: -54.78

3-Month Forecast: BMYs stock is expected to face downward pressure due to bearish technical indicators, with SMA200 above the current price. However, the low forward P/E may attract value investors, potentially stabilizing the price if fundamentals improve.